Key facts
- This page summarizes Andrew A. F. Hack's Form 4 filing for Nuvalent, Inc. (NUVL).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 13 Dec 2024, 16:30.
Andrew A. F. Hack - 11 Dec 2024 Form 4 Insider Report for Nuvalent, Inc. (NUVL)
- Reporting relationship
- Director
- Issuer ticker
- NUVL
- Reported as of
- 11 Dec 2024
- Net transaction value
- -$110,000,000
- SEC form
- 4
- Accepted by SEC
- 13 Dec 2024, 16:30:06 UTC
- Prior SEC filing
- 14 Jun 2024
- Next SEC filing
- 13 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Andrew Hack
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Andrew A. F. Hack filed Form 4 for Nuvalent, Inc. (NUVL) on 13 Dec 2024.
Change
- Previous filing in this sequence was filed on 14 Jun 2024.
- Current net transaction value: -$110,000,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NUVL
transaction
Class A Common Stock
Sale
- Transaction value
- $110,000,000
- Shares
- -1,250,000
- Change %
- -46%
- Price
- $88.00
- Shares after
- 1,447,267
- Date
- 11 Dec 2024
- Ownership
- See footnotes
- Footnotes
- F1, F2
NUVL
holding
Class A Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,499
- Date
- 11 Dec 2024
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents shares of Class A Common Stock held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS Fund II"), BCIP Life Sciences Associates, LP ("BCIPLS") and BCLS II Investco, LP ("BCLS II Investco" and, together with BCLS Fund II and BCIPLS, the "Bain Capital Life Sciences Entities").
Footnote F2
Bain Capital Life Sciences Investors, LLC ("BCLSI") is the ultimate general partner of each of BCLS Fund II and BCLS II Investco and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Partner of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.